

Haematologica
HAEMATOL/2019/224956
Version 4

The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

Debora Soncini, Stefania Orecchioni, Samantha Ruberti, Paola Minetto, Claudia Martinuzzi, Luca Agnelli, Katia Todoerti, Antonia Cagnetta, Maurizio Miglino, Marino Clavio, Paola Contini, Riccardo Varaldo, Micaela Bergamaschi, Fabio Guolo, Mario Passalacqua, Alessio Nencioni, Fiammetta Monacelli, Marco Gobbi, Antonino Neri, Giovanni Abbadessa, Sudharshan Eathiraj, Brian Schwartz, Francesco Bertolini, Roberto M. Lemoli, and Michele Cea

Disclosures: S.E., G.A., and B.S. are employees of ArQule, One Wall Street, Burlington, MA, USA. The rest of the authors have no relevant conflicts of interest to disclose.

Contributions: D.S. and M.C. wrote the manuscript; S.O. and F.B. performed the in-vivo experiments; D.S., S.R., P.M., P.C. and C.M. performed the in-vitro experiments; L.A., K.T. and A.N. performed genomic methodology and analysis data; A.C., M. M., M.C., R.V., M.B. and F.G. provided clinical samples; M.P. performed immunofluorescence analyses; A.N., F.M. and M.G. analyzed data; G.A., B.S. and S.E. provided ARQ531. The study was supervised by M.C and R.L.